4,517 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Acquired by OMERS ADMINISTRATION Corp

OMERS ADMINISTRATION Corp purchased a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 4,517 shares of the biopharmaceutical company’s stock, valued at approximately $1,360,000.

Other large investors have also modified their holdings of the company. iA Global Asset Management Inc. increased its stake in shares of Alnylam Pharmaceuticals by 979.5% during the 4th quarter. iA Global Asset Management Inc. now owns 17,780 shares of the biopharmaceutical company’s stock worth $7,070,000 after purchasing an additional 16,133 shares in the last quarter. SCS Capital Management LLC purchased a new stake in Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $34,784,000. Hussman Strategic Advisors Inc. acquired a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at $2,505,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Alnylam Pharmaceuticals during the 2nd quarter valued at $50,773,000. Finally, Hsbc Holdings PLC increased its position in Alnylam Pharmaceuticals by 22.6% during the fourth quarter. Hsbc Holdings PLC now owns 89,517 shares of the biopharmaceutical company’s stock worth $35,675,000 after buying an additional 16,503 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insider Buying and Selling

In other news, Director David E. I. Pyott sold 3,830 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the transaction, the director owned 1,582 shares of the company’s stock, valued at $473,302.76. This represents a 70.77% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $239.00 on Thursday. The stock has a market capitalization of $31.98 billion, a price-to-earnings ratio of 44.42 and a beta of 0.30. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75. Alnylam Pharmaceuticals, Inc. has a 52-week low of $197.81 and a 52-week high of $495.55. The stock’s fifty day simple moving average is $264.27 and its 200-day simple moving average is $294.77.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 EPS for the quarter, beating the consensus estimate of $1.63 by $0.21. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The firm had revenue of $1.29 billion during the quarter, compared to analyst estimates of $1.32 billion. During the same period in the prior year, the firm posted ($0.51) earnings per share. The business’s quarterly revenue was up 66.9% compared to the same quarter last year. Equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post 6.59 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on ALNY shares. BMO Capital Markets initiated coverage on Alnylam Pharmaceuticals in a report on Wednesday, August 19th. They issued an “outperform” rating and a $318.00 price target for the company. Chardan Capital reaffirmed a “buy” rating and set a $425.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, July 31st. Wells Fargo & Company dropped their price objective on Alnylam Pharmaceuticals from $316.00 to $256.00 and set an “equal weight” rating for the company in a research report on Friday, August 14th. Royal Bank Of Canada cut their target price on shares of Alnylam Pharmaceuticals from $445.00 to $350.00 and set an “outperform” rating for the company in a research note on Friday, July 31st. Finally, Bank of America decreased their price target on shares of Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating on the stock in a research note on Tuesday, July 14th. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $386.14.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.